823 results on '"Corsini, Alberto"'
Search Results
2. Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study
3. Does grant funding foster research impact? Evidence from France
4. PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
5. Pollution from fine particulate matter and atherosclerosis: A narrative review
6. Bempedoic Acid: for Whom and When
7. LDL-cholesterol control in the primary prevention of cardiovascular diseases: An expert opinion for clinicians and health professionals
8. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
9. The Role of High-Density Lipoprotein Cholesterol in 2022
10. What makes a productive Ph.D. student?
11. Lipid-lowering approaches to manage statin-intolerant patients
12. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
13. Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
14. Drug–Drug Interaction with DOACs
15. Atrial fibrillation and ischemic heart disease: (un)solved therapeutic dilemma?
16. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
17. Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance
18. Mapping fuel poverty risk at the municipal level. A small-scale analysis of Italian Energy Performance Certificate, census and survey data
19. Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact
20. Risk Factors for SAMS
21. The XVII National Congress of the Società Italiana di Terapia Clinica e Sperimentale (SITeCS)
22. PURPL and NEAT1 Long Non-Coding RNAs Are Modulated in Vascular Smooth Muscle Cell Replicative Senescence
23. Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3
24. Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study.
25. Drug–Drug Interactions of FXI Inhibitors: Clinical Relevance.
26. LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters
27. LDL Cholesterol Variability Impacts the Prognosis of Patients with Chronic Ischemic Heart Disease: A Real-World Italian Experience
28. Mechanism of bempedoic acid induced cholelithiasis: a role for statins to limit this adverse effect?
29. PCSK9 inhibition and inflammation: A narrative review
30. Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice
31. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
32. Lipid Lowering Drugs: Present Status and Future Developments
33. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?
34. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy
35. Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?
36. Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists
37. Focus sulla triplice combinazione precostituita ramipril, amlodipina e idroclorotiazide.
38. Proteomics Studies Suggest That Nitric Oxide Donor Furoxans Inhibit In Vitro Vascular Smooth Muscle Cell Proliferation by Nitric Oxide-Independent Mechanisms
39. Replicative Senescence in Vascular Smooth Muscle Cells: PURPL and NEAT1 Long Non-Coding RNAs as New Senescence-Associated Biomarkers
40. Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study
41. Jornada de Grandes infraestructuras europeas de Ciencias Sociales y Humanidades en el CSIC: DARIAH y CLARÍN en el horizonte (11 de mayo de 2023)
42. Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
43. ABCA1 and HDL3 are required to modulate smooth muscle cells phenotypic switch after cholesterol loading
44. Incertezze nei fattori di rischio cardiovascolare: inibitori del cotrasportatore sodio-glucosio di tipo 2 per tutti i pazienti diabetici ad elevato rischio cardiovascolare e per tutti i pazienti con insufficienza renale indipendentemente dall’albuminuria? Agonisti del recettore del glucagon-like peptide-1 come arma contro l’obesità?
45. Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
46. Smooth Muscle Cell Phenotypic Switch Induced by Traditional Cigarette Smoke Condensate: A Holistic Overview
47. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages
48. Clinical Pharmacology of Statins: an Update
49. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement
50. The Non-Invasive Assessment of Circulating D-Loop and mt-ccf Levels Opens an Intriguing Spyhole into Novel Approaches for the Tricky Diagnosis of NASH
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.